deferoxamine has been researched along with Anoxia, Brain in 7 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The area of cerebral infarction was measured at three levels using video imaging methods." | 1.29 | Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia. ( Davis, J; Fridovich, I; MacMillan, V, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mergenthaler, P | 1 |
| Muselmann, C | 1 |
| Sünwoldt, J | 1 |
| Isaev, NK | 1 |
| Wieloch, T | 1 |
| Dirnagl, U | 1 |
| Meisel, A | 1 |
| Ruscher, K | 1 |
| Peeters, C | 1 |
| Hoelen, D | 1 |
| Groenendaal, F | 2 |
| van Bel, F | 2 |
| Bär, D | 1 |
| Palmer, C | 1 |
| Roberts, RL | 1 |
| Bero, C | 1 |
| MacMillan, V | 1 |
| Fridovich, I | 1 |
| Davis, J | 1 |
| Shadid, M | 1 |
| Buonocore, G | 1 |
| Moison, R | 1 |
| Ferrali, M | 1 |
| Berger, HM | 1 |
| Feng, Y | 1 |
| LeBlanc, MH | 1 |
| LeBlanc, EB | 1 |
| Parker, CC | 1 |
| Fratkin, JD | 1 |
| Qian, XB | 1 |
| Patel, DM | 1 |
| Huang, M | 1 |
| Smith, EE | 1 |
| Vig, PJ | 1 |
| Yoshida, H | 1 |
| Imaizumi, T | 1 |
| Tanji, K | 1 |
| Matsumiya, T | 1 |
| Sakaki, H | 1 |
| Kimura, D | 1 |
| Cui, XF | 1 |
| Kumagai, M | 1 |
| Tamo, W | 1 |
| Shibata, T | 1 |
| Hatakeyama, M | 1 |
| Sato, Y | 1 |
| Satoh, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for deferoxamine and Anoxia, Brain
| Article | Year |
|---|---|
A functional role of the cyclin-dependent kinase inhibitor 1 (p21(WAF1/CIP1)) for neuronal preconditioning.
Topics: Animals; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; Deferoxamine; Erythropoietin; Gene Expre | 2013 |
Deferoxamine, allopurinol and oxypurinol are not neuroprotective after oxygen/glucose deprivation in an organotypic hippocampal model, lacking functional endothelial cells.
Topics: Allopurinol; Animals; Antioxidants; Cell Death; Deferoxamine; Endothelium; Excitatory Amino Acid Ant | 2003 |
Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats.
Topics: Animals; Animals, Newborn; Brain Ischemia; Deferoxamine; Female; Hypoxia, Brain; Male; Rats | 1994 |
Failure of iron chelators to protect against cerebral infarction in hypoxia-ischemia.
Topics: Animals; Brain; Brain Ischemia; Carbon Monoxide; Cerebral Infarction; Deferoxamine; Hypoxia, Brain; | 1993 |
Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia.
Topics: Allopurinol; Animals; Animals, Newborn; Brain Ischemia; Cerebral Cortex; Deferoxamine; Hypoxia, Brai | 1998 |
Desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in piglets.
Topics: Animals; Animals, Newborn; Antioxidants; Asphyxia Neonatorum; Brain; Deferoxamine; Dose-Response Rel | 2000 |
Platelet-activating factor enhances the expression of vascular endothelial growth factor in normal human astrocytes.
Topics: Anti-Inflammatory Agents; Astrocytes; Brain; Cells, Cultured; Cycloheximide; Deferoxamine; Dexametha | 2002 |